Expression of a specific extracellular matrix signature is a favorable prognostic factor in acute myeloid leukemia
Valerio Izzi; Lakkala, Juho; Devarajan, Raman; Savolainen, Eeva-Riitta; Koistinen, Pirjo; Heljasvaara, Ritva; Pihlajaniemi, Taina (2017-12-13)
Valerio Izzi, Juho Lakkala, Raman Devarajan, Eeva-Riitta Savolainen, Pirjo Koistinen, Ritva Heljasvaara, Taina Pihjajaniemi, Expression of a specific extracellular matrix signature is a favorable prognostic factor in acute myeloid leukemia, Leukemia Research Reports, Volume 9, 2018, Pages 9-13, ISSN 2213-0489, https://doi.org/10.1016/j.lrr.2017.12.001
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).
https://creativecommons.org/licenses/by-nc-nd/4.0/
https://urn.fi/URN:NBN:fi-fe201901111991
Tiivistelmä
Abstract
Relapse of acute myeloid leukemia (AML) is still dramatically frequent, imposing the need for early markers to quantify such risk. Recent evidence point to a prominent role for extracellular matrix (ECM) in AML, but its prognostic value has not yet been investigated. Here we have investigated whether the expression of a 15-ECM gene signature could be applied to clinical AML research evaluating a retrospective cohort of 61 AML patients and 12 healthy donors. Results show that patients whose ECM signature expression is at least twice as that of healthy donors have considerably longer relapse-free survival, with further stage-specific therapy outcomes.
Kokoelmat
- Avoin saatavuus [34624]
